GLP-1 Diabetic Trulicity's High Flux

Sales of 15.8 billion won in the third quarter of this year

22% year-on-year increase

Trulicity

GLP-1 analog diabetes treatment Trulicity is on the rise.

 

In the third quarter of last year, sales increased by 22% compared to the same period last year, continuing to grow.

 

Attention is drawn to the competitive drug Ozempic.

 

The pharmaceutical industry predicts that Ozempic will be a strong opponent of Trulicity.

 

In the global market, Ozempic has already surpassed Trulicity sales.

 

According to IQVIA, a pharmaceutical market research firm, Trulicity's sales in the third quarter were 15.8 billion won.

 

It increased by 22.3% compared to 12.9 billion won in the third quarter of last year.

 

Trulicity is a GLP-1 analog diabetes treatment.

 

GLP-1 analogs are drugs developed using GLP-1 (Glucagon-Like Peptide-1) hormones that are involved in controlling blood sugar in the body.

 

GLP-1 hormones promote insulin secretion immediately after meals, lowering blood sugar, and reducing insulin secretion when blood sugar falls below a certain level to help prevent hypoglycemia.

 

Trulicity monopolizes the GLP-1 analog diabetes drug market.

 

As of the third quarter, the sales share reached 99.8%.

 

Trulicity received domestic item approval in May 2015 and released its salary in May 2016.

 

It was the latest GLP-1 analog diabetes drug to be released, but it grew steeply every quarter.

 

Since 2017, it has virtually solidified its dominance system.

 

At the same time, it is breaking new sales records every quarter.

 

In addition to Trulicity, Lyxumia, Victoza, and Byetta have entered the domestic market, but they seem to have been completely pushed out of the competition with Trulicity.

 

Lyxumia and Byetta withdrew their item permits and withdrew from the domestic market, while Victoza's quarterly sales fell to around 30 million won.

 

Ozempic & Rybelsus

The pharmaceutical industry's attention is focused on competitive products to be released by Novono Disc Pharmaceutical.

 

Novo Nordisk was granted Ozempic in April and Rybelsus in May.

 

Ozempic is a long-term, once-a-week injection of the same type as Trulicity, and Rybelsus is a drug that converts it into an oral drug.

 

Rybelsus is a once-a-day drug.

 

In the pharmaceutical industry, It includes an indication of reducing the risk of cardiovascular events compared to Trulicity.

 

Synergy with Rybelsus, the world's first oral GLP-1 analog, is also expected.

 

In the global market, Ozempic has already overtaken Trulicity.

 

According to a quarterly report by Eli Lilly and Novo Nordisk as of the second quarter, Ozempic's global sales in the second quarter amounted to $1.986 billion.

 

During this period, Trulicity's global sales were $1.94 billion.